The Purposes of the Geisinger Clinical Oncology Program are to: 1) enter large numbers of patients with cancer into NCI-approved treatment and cancer control clinical trials, bringing state-of-the-art cancer care into a large rural population of Pennsylvania; 2) use the large, multispecialty group practice structure of the Geisinger Clinic to involve primary health care providers as well as a wider cross-section of medical and surgical specialists in cancer treatment and control research; and 3) extend cancer control efforts of the CCOP to the Geisinger System, involving a wide geographic area and many primary care practice sites with screening, detection, prevention, ongoing care, rehabilitation activities through CCOP protocols. There are many special aspects of Geisinger that favor continuation of our CCOP: 1.Large cancer patient population; huge overall patient numbers (over 1 million outpatient visits annually for the Geisinger System). 2.Stable, very experienced CCOP staff. 3.A 6-year record of successful accrual to both NCI-approved cancer treatment and cancer control protocols, with consistent, superb data quality. 4.Geisinger's excellent medical record system, with unit patient charts. 5.All needed treatment specialists available under one roof, with a large, full-time salaried multispecialty physician staff. 6.Geisinger CCOP's record of active involvement with research bases, with several protocol chairmanships, committee memberships, authored publications. 7.Our long-standing interest in cancer control research, as evidenced by prior in-house original studies, and cancer control protocols chaired for NCCTG. 8.Availability of large primary care network for future large scale control trials. 9.Very strong institutional commitment to clinical trials research in cancer. We propose that our CCOP retain the North Central Cancer Treatment Group as our primary base (includes a secondary affiliation with ECOG through Mayo Clinic). The Radiation Therapy Oncology Group and the Childrens' Cancer Study Group will be our secondary bases. This variety allows all the physicians to play a major role in their modality's group, not just as a """"""""supporting character"""""""" for the medical oncologists. It also suits our tertiary care institution, since rare tumors are seen here with some frequency.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (54))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weis Center for Research-Geisinger Clinc
United States
Zip Code
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Patel, Krishna; Foster, Nathan R; Farrell, Ann et al. (2013) Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 28:770-6
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 115 publications